Dermal fillers on FDA’s radar
This article was originally published in The Gray Sheet
Executive Summary
Agency is putting together a "Post Market Issue Action Team" to address complaints about the long-term effects of dermal fillers, Peter Rumm, deputy director of general, restorative and neurological devices at the Office of Device Evaluation, says Sept. 17. Allergan gained expanded labeling in June for treatment effects lasting up to one year with its Juvederm Ultra and Juvederm Ultra Plus dermal fillers (1"The Gray Sheet" July 2, 2007, In Brief). BioForm Medical (Radiesse) and Artes Medical (ArteFill) are among other firms seeking longer-lasting indications
You may also be interested in...
Allergan’s Juvederm
Anti-aging dermal fillers Juvederm Ultra and Juvedermm Ultra Plus gain expanded labeling approval from FDA for treatment effects lasting up to one year - longer than any other hyaluronic acid-based filler, according to Allergan. Competing treatments include Medicis' Restylane HA-based dermal filler...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.